125 results about "Alpha chain" patented technology

The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

The present invention discloses a T cell receptor, which specifically binds to a KRAS gene codon 12 mutation G12D 26aa peptide, wherein the amino acid sequence of the peptide is represented by SEQ IDNO:1 MTEYKLVVVGADGVGKSALTIQLIQN, the 9-12aa epitope polypeptide with high affinity is represented by SEQ ID NO:48 VVVGADGVGK and SEQ ID NO:49 KLVVVGADGVGK when the T cell receptor can identify the HLAmolecule antigen complex, and the HLA molecule is HLA-A0301. The invention discloses the amino acid sequences of the alpha chain and the beta chain of the T cell receptor in the identification of theantigen complex formed by the KRAS gene G12D mutation peptide and the HLA-A0301, nucleotide sequences encoding the alpha chain and the beta chain of the T cell receptor, a vector containing the nucleotide sequences, cells containing the nucleotide sequences, and applications of the vector or the cells in preparation of drugs for prevention and treatment of diseases related to KRAS gene mutation.

The present invention relates to monoclonal antibodies which recognize defined regions of the T-cell receptor (TCR). In a specific embodiment, the invention provides monoclonal antibodies which are reactive with a constant region of the alpha chain of the TCR. In particular embodiments, the invention relates to two monoclonal antibodies, termed alpha F1 and alpha F2, which react with two different epitopes on the framework region of the alpha monomer of the TCR molecule. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the beta chain of the TCR. In particular, the invention provides two monoclonal antibodies, termed W112 and 2D1, which react with beta chain variable regions V beta 5.3 and V beta 8.1, respectively. In another specific embodiment, the invention is directed to monoclonal antibodies reactive with a variable region of the delta chain of the TCR. In particular, the invention provides monoclonal antibody delta TCS1, isotype IgG2a. The monoclonal antibodies of the invention have value in diagnosis and therapy and are useful tools for study of the immune system.

The present invention provides a combination of two or more isolated or purified anti-C5 antibodies, wherein the isolated or purified anti-C5 antibodies bind to an epitope within the beta chain or alpha chain of C5 and wherein the isolated or purified anti-C5 antibodies to be combined do not compete with each other for binding to the epitope. Methods of using the combination for treating an individual having a complement-mediated disease or condition which involves excessive or uncontrolled activation of C5, or for enhancing the clearance of C5 from plasma in an individual, are also provided.

The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs may consist essentially of TCRs which may comprise an alpha chain variable domain from a natural repertoire and a beta chain variable domain from a natural repertoire, wherein the alpha chain variable domain may comprise a TRAV12-2 or a TRAV21 gene product and the beta chain variable domain may comprise a TRBV6 gene product.

The invention discloses a chimeric antigen cell receptor and application thereof, and relates to the technical field of biology. The chimeric antigen cell receptor comprises an antigen binding structure domain, an alpha chain and a beta chain, wherein the alpha chain and the beta chain are connected with the antigen binding structure domain; the antigen binding structure domain is an antibody Fabfragment; the antibody has the characteristic combined with target protein specificity. Immune cells for expressing the chimeric antigen cell receptor can be combined with target proteins on target cells; activating signals are transmitted; immune cells are activated, so that the target cells for expressing the target proteins are killed; the process does not depend on MHC molecules for submissionof target proteins. The chimeric antigen cell receptor can be applied to the preparation of corresponding antitumor medicine, and is used in the fields of malignant cell clearing, autoimmune diseasetreatment and the like.

The invention discloses a method for breeding IL-12p40 (-/-) IL-2R alpha (-/-) mice used as novel hepatic fibrosis and primary biliary cirrhosis animal models. The method includes steps of (1), performing cross breeding on IL-2R alpha (+/-) mice and IL-12p40(-/-) mice to obtain IL-12p40(+/-) IL-2R alpha (+/-) mice by means of breeding; (2), performing cross breeding on IL-12p40(-/-) mice and the IL-12p40(+/-) IL-2R alpha (+/-) mice obtained in the step (1) to obtain IL-12p40(-/-) IL-2R alpha (+/-) mice by means of breeding; (3), performing inbreeding on the IL-12p40(-/-) IL-2R alpha (+/-) mice obtained in the step (2) and obtaining the identified IL-12p40(-/-) IL-2R alpha (-/-) mice. The method has the advantages that IL-12p40 is an important cell factor in the immune system of a patient, and functions and differentiation of CD4+T and CD8+T cells can be affected by the IL-12p40; IL-2R alpha is an alpha chain of an IL-2 receptor and plays a key role in keeping the balance of the immune system of the patient.

The invention relates to a chimeric antigen receptor of target CD19 and application of the chimeric antigen receptor. Specifically, the invention provides a fusion protein, and the fusion protein is selected from the followings: (1) a fusion protein containing leader peptide of CD8 antigen, an anti-CD19 single-chain antibody, a human CD8 alpha chain region, a human CD28 transmembrane region, a human CD28 intracellular region and a human CD3 zeta intracellular region which are connected in sequence; and (2) a (1) derived fusion protein retaining activated T cell activity by replacing, losing or adding one or more amino acids in a (1) limited amino acid sequence. The invention also provides a coding sequence of the fusion protein, a carrier containing the coding sequence, and application of the fusion protein, the coding sequence and the carrier.

A method of producing collagen in a plant and plants producing collagen are provided. The method is effected by expressing in the plant at least one type of a collagen alpha chain in a manner enabling accumulation of the collagen alpha chain in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant.

The invention relates to a urine protein marker of breast cancer and applications thereof in diagnosis and prognosis. Specifically, the invention relates to applications of the urine protein marker of breast cancer in early diagnosis and disease monitoring of human breast cancer. The urine protein marker comprises beta-2 microglobulin, alpha-1-acid glycoprotein 1, programmed cell death 6 interacting protein, haptoglobin related protein, addiment C4-A, apolipoprotein A-IV, calcium binding protein, HLA-I histocompatibility antigen, A-3 alpha chain, pancreatic stone protein 1 alpha, blood coagulation factor XII, collectin 12, galectin-3 binding protein, vitamin D binding protein, and the like.

This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.

The present invention relates to novel fusion proteins comprising a bacteriophage coat protein and a single-chain T cell receptor and uses of such complexes. In one aspect, the invention relates to soluble fusion protein comprising a bacteriophage coat protein covalently linked to a single-chain T cell receptor which comprises a V-alpha chain covalently linked to a V-beta chain by a peptide linker sequence. The soluble fusion proteins of the invention are useful for a variety of applications including: 1) making a bacteriophage library for displaying single-chain T cell receptors for use in screens for identification and isolation of ligands that bind single-chain T cell receptors, and 2) methods for isolating soluble and fully functional single-chain T cell receptors from the fusion proteins.

The invention discloses a preparation method and application of a fluorescent and radioactive core cord double-labeled targeting imaging agent, belonging to the field of preparation and application of molecular imaging agents in the field of biomedicine. The compound of the present invention is 111In-DTPA-Bz-NH-SA-K(IR-783-S-Ph-CO)-c(CGRRAGGSC)NH2, which is called a double-labeled imaging agent for interleukin 11 receptor alpha chain. The invention consists of three parts: fluorescent imaging agent IR-783-S-Ph-COOH, radionuclide indium-111 and circulating polypeptide. Circulating polypeptide (1) is an ideal carrier of contrast agent, which can be targeted to IL-11Rα chain. The fluorescent imaging agent (2) is connected to the circulating polypeptide through the functional group of lysine. The radionuclide indium-111(3) is first chelated with a metal chelator, and then linked to the circulating polypeptide through the functional group of lysine.

The invention discloses a method for extracting undenatured natural collagen from sucking pig skin. The method is characterized in that treatment is carried out by sub-step repeated different combinations in a manner that a degreasing agent is assisted by intermittent ultrasonic waves, an unhairing agent and a non-collagen removing agent are respectively used for unhairing and removing non-collagen, and no hair root exists in the skin after unhairing, wherein shown by determination, the fat content is lower than 0.5% and the ash content is lower than 0.3%; enzyme-soluble collagen is obtained through leaching by acetic acid-protease and is purified by high-speed centrifugation, sodium chloride salting-out and dialysis, and spongy sucking pig skin collagen is obtained after freeze-drying, wherein the collagen extraction ratio exceeds 50% (dry weight), and shown by electrophoretogram, the sucking pig skin collagen contains a beta chain and an alpha chain, of which the molecular weights are 200000 and 100000 respectively, and is free from other hybrid protein bands, so that the collagen reserves three helical structures and has relatively high purity.